Amarin Corp. (AMRN) Appoints Tom Reilly as New Chief Financial Officer

Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin --

-- Michael W. Kalb to Depart Amarin to Pursue Other Interests --

Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of Tom Reilly as Chief Financial Officer, effective June 20, 2022. The appointment follows the resignation of Michael W. Kalb who will leave the Company to pursue other interests after a brief transition period.

“We are delighted to welcome Tom Reilly to the Amarin executive leadership team. Tom’s significant financial leadership experience across large global pharma and biotechnology companies as well as his proven track record leading financial planning and analysis within international and commercial operations will be a great asset to Amarin as we expand around the world. I look forward to working closely with Tom to execute on our European and international objectives,” said Karim Mikhail, president and chief executive officer of Amarin. “I would like to thank Mike for his years of service to Amarin. On behalf of the entire Amarin team, I wish him continued success in his future endeavors.”

“Tom’s appointment exemplifies our commitment to enhance our leadership team and board with the right talent to support the Company’s BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide,” concluded Mr. Mikhail.

“I am excited to be joining Amarin at this important juncture in the Company’s global expansion, and I look forward to bringing my experiences to bear in executing disciplined financial management and leadership that will support the Company’s growth in the years to come,” said Mr. Reilly.

Tom Reilly is an experienced senior leader with significant expertise in corporate and commercial finance in the pharmaceutical and biotechnology sectors. Most recently, he served as Chief Financial Officer for Cara Therapeutics, where he was responsible for leading all aspects of Cara’s financial operations and planning. Prior to his role at Cara, Mr. Reilly served as Head of Finance for the U.S. General Medicines unit at Allergan, where he led all financial management for that business. Prior to Allergan, Mr. Reilly spent 14 years with Novartis where he served in roles of increasing responsibility, including Finance Head for the Novartis Oncology Development unit, CFO for Novartis Pharma Austria, Financial Controller for Novartis USA’s Pharmaceutical Division as well as a series of roles supporting Novartis’ financial planning and analysis and accounting. Earlier in his career, Mr. Reilly served in financial planning and finance roles at Pharmacia.

Mr. Reilly holds a Bachelor of Science in Finance from Manhattan College and a Master of Business Administration in Accounting from Seton Hall University.

You May Also Be Interested In

• Arista Networks (ANET) Announces COO Resignation
• Peapack-Gladstone Financial (PGC) Appoints Kate Sant'Angelo as SVP, Director of Personal Banking
• Snail (SNAL) Announces Resignation of Chief Strategy Officer and Chairman